Calliditas Therapeutics AB and STADA Arzneimittel AG announced that they have entered into a license agreement to register and commercialize a novel specialty drug candidate for the treatment of the chronic autoimmune kidney disease Immunoglobulin A Nephropathy (IgAN) in the European Economic Area (EEA) member states, Switzerland and the UK. Under the terms of the agreement, Calliditas is entitled receive an initial upfront payment of EUR 20 million ($24 million) upon signing and up to an additional EUR 77.5 million ($91 million) in future payments linked to pre-defined regulatory and commercialization milestones. STADA is also obligated pay tiered royalties on net sales expressed as a percentage between the low twenties and the low thirties.